PSMA-PET/CT检测临床显著前列腺癌的成本效果研究
该研究采用终身决策模型,比较以MRI驱动的标准诊断路径(PI-RADS 3-5分者行前列腺活检)与加入PSMA-PET/CT以避免不必要活检的策略。在PI-RADS 3病变中,PSMA-PET/CT使每患者QALY增加0.002,每患者费用增加170-186欧元,ICER为56,700-93,212欧元/QALY,处于临界成本效果;在PI-RADS 1-2中,QALY减少0.001,费用增加416-429欧元,不具有成本效果。
要点
- PI-RADS 3病变加做PSMA-PET/CT每患者QALY增加0.002,费用增加170-186欧元,ICER为56,700-93,212欧元/QALY。
- PI-RADS 1-2病变加做PSMA-PET/CT每患者QALY减少0.001,费用增加416-429欧元,不具有成本效果。
- MRI结果不明确时加做PSMA-PET/CT似乎处于临界成本效果,因避免活检并减少惰性低危肿瘤检出。
核心结论
- 在MRI结果不明确的患者中,MRI基础上加做PSMA-PET/CT似乎处于临界成本效果,归因于避免活检和减少惰性低危肿瘤检出。
- 在MRI阴性的男性中,加做PSMA-PET/CT似乎不具有成本效果,归因于不必要的活检数量更多且临床显著前列腺癌检出仅轻微改善。
研究设计与样本
- 终身决策模型,比较MRI驱动的标准诊断路径(PI-RADS 3-5分行前列腺活检)与加入PSMA-PET/CT以可能避免不必要活检的策略。
- 计算每种策略的长期质量调整生命年(QALY)和医疗费用。
主要发现
- PI-RADS 3病变中,PSMA-PET/CT使每患者QALY增加0.002,每患者费用增加170-186欧元,ICER为56,700-93,212欧元/QALY,处于临界成本效果。
- PI-RADS 1-2中,额外活检和低危前列腺癌过度检出导致每患者QALY减少0.001,每患者费用增加416-429欧元,因此不具有成本效果。
关键数值与推荐
- PI-RADS 3病变:每患者QALY增加0.002,费用增加170-186欧元,ICER 56,700-93,212欧元/QALY。
- PI-RADS 1-2病变:每患者QALY减少0.001,费用增加416-429欧元。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) is currently under evaluation for detecting clinically significant prostate cancer. The PSMA-PET/CT may complement the current standard diagnostic pathway for prostate cancer, which includes prostate-specific antigen (PSA) testing and multiparametric magnetic resonance imaging (mpMRI). This study evaluated the cost-effectiveness and quality of life impact of incorporating PSMA-PET/CT into this diagnostic algorithm. METHODS: A life-time decision model compared the current standard of care of a MRI driven diagnostic pathway, where men undergo prostate biopsy in case of a Prostate Imaging Reporting and Data System (PI-RADS) scores 3-5, to a strategy incorporating PSMA-PET/CT to potentially avoid unnecessary biopsies. Long-term quality-adjusted life years (QALY) and healthcare costs were calculated for each approach. RESULTS: In PI-RADS 3 lesions, PSMA-PET/CT improved the per-patient QALY by 0.002 and was borderline cost-effective, with an increased cost of €170-€186 per patient and an incremental cost-effectiveness ratio (ICER) of €56,700-€93,212 per QALY. In PI-RADS 1-2, additional biopsies and over-detection of low-risk prostate cancers led to a per-patient QALY decrease of 0.001 points, a cost increase of €416-€429 per patient and was thus not cost-effective. CONCLUSION: The addition of PSMA-PET/CT to MRI in patients with equivocal MRI findings appears to be borderline cost-effective due to biopsy avoidance and a reduced detection of indolent, low-risk tumors. In men with a negative MRI, adding a PSMA-PET/CT does not seem to be cost-effective due to a higher number of unnecessary biopsies and only minor improvement in the detection of clinically significant prostate cancer.
引用
- Privé BM, Govers TM, Israël B, et al. A cost-effectiveness study of PSMA-PET/CT for the detection of clinically significant prostate cancer. Eur J Nucl Med Mol Imaging. 2025. PMID: 40072531. doi:10.1007/s00259-025-07190-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。